Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

FDA Approves Bayer Kerendia for Type 1 Diabetes CKD

Analysis based on 11 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026

Sentiment
15
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands Bayer's Kerendia franchise into a new indication with no approved competition in over three decades, potentially adding meaningful revenue growth for the company's pharmaceuticals division and supporting its stock. Broader market impact is limited, as the news is company-specific and unlikely to move major indexes, though it reinforces positive sentiment for the pharmaceutical sector and kidney disease treatment developers.

pharmaceuticals biotechnology healthcare

Bayer announced on September 17, 2026 that the U.S. United States — Food and Drug Administration approved Kerendia (finerenone) for the treatment of adult patients with chronic kidney disease associated with type 1 diabetes. The approval marks the first new FDA-approved treatment option in more than 30 years for this patient population and represents the third approved U.S. indication for Kerendia, following its 2021 approval for chronic kidney disease associated with type 2 diabetes and its 2025 approval for symptomatic chronic heart failure with left ventricular ejection fraction of at least 40 percent. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist sold in 10 mg and 20 mg doses, is now indicated to reduce the urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and end-stage kidney disease. The decision follows the FDA's Priority Review of Bayer's supplemental New Drug Application, granted in May 2026, and is supported by results from the Phase III FINE-ONE trial in adults with CKD and type 1 diabetes, along with additional Phase III data from the FIDELIO-DKD and FIGARO-DKD trials in CKD associated with type 2 diabetes. In FINE-ONE, finerenone plus standard of care significantly reduced the primary endpoint of relative change in UACR by 25 percent over six months compared with placebo. The FINE-ONE results were published in the The New England Journal of Medicine in March 2026 and presented in November 2025 at the American Society of Nephrology's Kidney Week. Approximately 20-30 percent of people with type 1 diabetes in the U.S. also have CKD. With this decision, the U.S. is the only country where Kerendia is approved for the treatment of adults with chronic kidney disease associated with type 1 diabetes. Bayer shares were trading at 48.98 euros at previous close on the Frankfurt Exchange.

stock
Bayer received FDA approval for Kerendia in a new type 1 diabetes CKD indication, its third U.S. indication for the drug, strengthening its pharmaceutical portfolio and long-term revenue prospects.
Importance 100.0 Sentiment 45.0
govactor
The FDA approved Kerendia for the new indication and previously granted Priority Review, enabling the first new treatment option in over 30 years for this patient population.
Importance 85.0 Sentiment 10.0
cnt
The U.S. is the only country where Kerendia is approved for type 1 diabetes CKD, highlighting the FDA's regulatory role and the large addressable patient population.
Importance 40.0 Sentiment 10.0
ngo
The association's 30 percent UACR reduction threshold was cited as a benchmark associated with slower CKD progression, supporting the clinical relevance of the approval.
Importance 15.0 Sentiment 5.0
exch
Bayer shares traded at 48.98 euros at previous close on the exchange, serving as the reference point for the stock's reaction to the approval news.
Importance 15.0 Sentiment 5.0
cnt
Kerendia is approved in China for type 2 diabetes CKD and heart failure, and marketing applications for non-diabetic CKD have been filed there, but the new type 1 diabetes indication is U.S.-only.
Importance 10.0 Sentiment 0.0
alliance
Kerendia is approved in European Union — Europe for type 2 diabetes CKD and heart failure, but the new type 1 diabetes indication is currently limited to the U.S.
Importance 10.0 Sentiment 0.0
cnt
Kerendia is approved in Japan for type 2 diabetes CKD and heart failure, with non-diabetic CKD applications filed, but the new type 1 diabetes indication is U.S.-only.
Importance 10.0 Sentiment 0.0
ngo
The FINE-ONE results were presented at the society's Kidney Week in November 2025 as a Featured High-Impact Clinical Trial, lending scientific credibility to the approval.
Importance 10.0 Sentiment 5.0
priv
The journal published the FINE-ONE trial results in March 2026, providing peer-reviewed evidence supporting the FDA approval.
Importance 10.0 Sentiment 5.0
curr
The euro is the currency in which Bayer's Frankfurt-listed shares are priced, relevant for European Union — European investors assessing the stock's reaction.
Importance 5.0 Sentiment 0.0
Bayer related ↔ United States
United States strategic rival ↔ China The United States perceives China as a strategic rival, actively implementing sanctions and export controls, while addre
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
China related ↔ European Union
China rivals ↔ Japan China views Japan as a strategic rival, actively challenging its stance on Taiwan and territorial claims. China has impo
European Union related ↔ Japan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.